Elacestrant Impresses in EMERALD Trial of Breast Cancer

Elacestrant Impresses in EMERALD Trial of Breast Cancer

Breast Cancer, Oncology News & Insights, Targeted Oncology

Promising Phase III Results in HR+/HER2- Breast Cancer

Elacestrant in management of ER-Positive, HER2-Negative BC

Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements? - ScienceDirect

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements? - ScienceDirect

Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial - The ASCO Post

Paolo Tarantino on X: EMERALD trial: significant, albeit modest PFS improvement with elacestrant vs AI/fulvestrant in ET-pretreated MBC patients Good tolerability for elacestrant, with main AE being nausea. Could become the first